Affordable Access

Publisher Website

Synergistic antiproliferative effects of interleukin-1α and doxorubicin against the human ovarian carcinoma cell line (NIH : OVCAR-3)

Authors
Journal
Biochemical Pharmacology
0006-2952
Publisher
Elsevier
Publication Date
Volume
45
Issue
10
Identifiers
DOI: 10.1016/0006-2952(93)90022-o
Disciplines
  • Medicine

Abstract

Abstract Interieukin-1α (IL-1α) exerts antiproliferative effects on a human ovarian carcinoma cell line, NIH : OVCAR-3, which is resistant to clinically relevant concentrations of doxorubicin (DOX) and other chemotherapeutic agents. This action of IL-1α depends on the presence of type I (80 kDa) receptors, although no quantitative relationship has been established between receptor occupancy and inhibition of cell growth. When NIH : OVCAR-3 cells were exposed to IL-1α and DOX in combination, a mutual potentiation of the antiproliferative effects of the two agents was observed. This synergistic effect was not due to IL-1 receptor expression up-regulation by DOX, and receptor-dependent intemalization of the cytokine was also unaffected. The involvement of IL-1 receptors is supported by the observation that synergism between the two agents was diminished (but not abolished) in the presence of a specific IL-1 receptor antagonist at concentrations blocking more than 75% of IL-1α binding. DOX was found to significantly increase IL-1α accumulation by NIH : OVCAR-3 cells after long-term (48 hr) exposure to the cytokine at 37°, which might be due to increased nonspecific fluid phase uptake or to interference with cytokine degradation and/or release processes. The potent synergy of IL-1α and DOX against ovarian carcinoma cells in vitro suggests that this drug combination may be effective against this disease in the clinic.

There are no comments yet on this publication. Be the first to share your thoughts.